DR. MARK H GINSBERG, M.D.
Osteopathic Medicine at Arbor Dr, San Diego, CA

License number

California G29521

Personal information

See more information about MARK H GINSBERG at radaris.com

Name

Address

Phone

Mark Ginsberg

PO Box 2480, Avila Beach, CA 93424

Mark Ginsberg, age 63

102 Cresta Dr, Boulder Creek, CA 95006

(831) 566-7354

Mark Ginsberg, age 57

13536 Whitewater Dr, Poway, CA 92064

Mark Ginsberg

23535 Calistoga Pl, Ramona, CA 92065

(760) 787-0479

Mark Ginsberg, age 79

2944 Renault Pl, San Diego, CA 92122

(858) 344-2609

Professional information

See more information about MARK H GINSBERG at trustoria.com

Mark Howard Ginsberg, La Jolla CA

Specialties:

Rheumatologist

Address:

9500 Gilman Dr, La Jolla, CA 92093
200 W Arbor Dr, San Diego, CA 92103

Education:

State University of New York Downstate Medical Center, College of Medicine - Doctor of Medicine
Bernard Mitchell Hospital-University of Chicago Hospitals - Fellowship - Rheumatology (Internal Medicine)
Bernard Mitchell Hospital-University of Chicago Hospitals - Residency - Family Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)

Dr. Mark H Ginsberg, San Diego CA - MD (Doctor of Medicine)

Specialties:

Rheumatology

Address:

200 W Arbor Dr SUITE 726, San Diego 92103
(619) 543-6248 (Phone), (619) 543-2381 (Fax)
San Diego Office
200 W Arbor Dr, San Diego 92103
(858) 657-7000 (Phone), (619) 543-3183 (Fax)
UCSD SCHOOL OF MEDICINE
9500 Gilman Dr, La Jolla 92093
(858) 822-5666 (Phone)

Certifications:

Internal Medicine, 1973, Rheumatology, 1974

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Suny Downstate Medical Center
Graduated: 1970
U Chicago Hosp
The University Of Chicago Medical Center

Peptides And Antibodies That Inhibit Platelet Adhesion

US Patent:

5114842, May 19, 1992

Filed:

Mar 31, 1988

Appl. No.:

7/175342

Inventors:

Edward F. Plow - San Diego CA
Mark H. Ginsberg - San Diego CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12Q 100, A61K 3700, A61K 4900, C07K 700

US Classification:

424 858

Abstract:

A polypeptide analog capable of immunologically mimicking a linear hGPIIb antigenic determinant expressed when platelet-associated GPIIb-IIIa binds fibrinogen is disclosed. An antibody that immunoreacts with the polypeptide and hGPIIb when hGPIIb is present as a platelet-associated GPPIb-IIIa/fibrinogen complex is also disclosed. Further disclosed are diagnostic systems and methods for assaying fibrinogen-bound platelets in a vascular fluid sample using the polypeptides and/or antibodies of the invention.

Peptides And Antibodies That Inhibit Platelet Adhesion

US Patent:

5498499, Mar 12, 1996

Filed:

May 15, 1992

Appl. No.:

7/883669

Inventors:

Edward F. Flow - San Diego CA
Mark H. Ginsberg - San Diego CA
Joseph C. Loftus - Carlsbad CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 4900, A61K 3900, G01N 3353

US Classification:

435 721

Abstract:

A polypeptide analog capable of immunologically mimicking a linear hGPIIb antigenic determinant expressed when platelet-associated GPIIb-IIIa binds fibrinogen is disclosed. An antibody that immunoreacts with the polypeptide and hGPIIb when hGPIIb is present as a platelet-associated GPIIb-IIIa/fibrinogen complex is also disclosed. Further disclosed are diagnostic systems and methods for assaying fibrinogen-bound platelets in a vascular fluid sample using the polypeptides and/or antibodies of the invention.

Structural Models For Cytoplasmic Domains Of Transmembrane Receptors

US Patent:

2003022, Dec 4, 2003

Filed:

May 27, 2003

Appl. No.:

10/447292

Inventors:

Mark Ginsberg - San Diego CA, US
Martin Pfaff - Seyssins, FR

International Classification:

G01N033/53, C07K014/705, C07K016/28

US Classification:

435/007100, 530/350000, 530/388220

Abstract:

Polypeptides containing a series of heptad-repeats that mimic a transmembrane domain and a selected cytoplasmic domain attached to the series of heptad repeats are provided which can be used in construction of structural models for evaluating the structure and activity of occupied, clustered and heteromeric transmembrane proteins and identifying therapeutic compounds.

Polypeptides For Promoting Cell Attachment

US Patent:

6316412, Nov 13, 2001

Filed:

Dec 1, 1998

Appl. No.:

9/201970

Inventors:

Mark H. Ginsberg - San Diego CA
Edward F. Plow - San Diego CA
Ronald Bowditch - Encinitas CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 3800, A61K 3804, C07K 100, C07K 1600

US Classification:

514 15

Abstract:

Novel polypeptides derived from human fibronectin are described which bind to integrin receptors expressed by cells. The receptor binding site of human fibronectin begins at amino acid residue 1394 and ends at residue 1400 of fibronectin. The polypeptides facilitate attachment of cells to substrates either alone or in conjunction with RGD-containing peptides. Vectors, fusion proteins and antibodies are also described. Methods for promoting cell attachment and for inhibiting cell adhesion are also described.

Characterization Of Platelet Aggregation Disorders

US Patent:

5196309, Mar 23, 1993

Filed:

Nov 15, 1990

Appl. No.:

7/614723

Inventors:

Mark H. Ginsberg - San Diego CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

G01N 33567, G01N 33577

US Classification:

435 721

Abstract:

Methods are described for characterizing platelet aggregation defects. The defects are characterized as activation, ligand binding, or post-occupancy defects. In one embodiment of the invention a Cam variant of Glanzmann's thrombasthenia is characterized as having a ligand binding defect. In another embodiment, a patient with myelofibrosis is identified as having an activation defect. Rapid analysis are afforded using fluorescence-activated flow cytometry. Also, diagnostic kits are described which comprise antibodies suitable for characterizing the above defects.

Peptides And Antibodies That Inhibit Integrin-Ligand Binding

US Patent:

5196511, Mar 23, 1993

Filed:

Dec 1, 1989

Appl. No.:

7/444777

Inventors:

Edward F. Plow - San Diego CA
Stanley E. D'Souza - San Diego CA
Mark H. Ginsberg - San Diego CA

Assignee:

The Scripps Research Institute - San Diego CA

International Classification:

C07K 706, C07K 708, C07K 710, C07K 1528

US Classification:

530324

Abstract:

Polypeptides which are derived from the ligand-binding portion of an Integrin alpha subunit are disclosed as are their use for modulation of Integrin ligand binding. Anti-peptide antibodies, hybridomas secreting these antibodies, as well as methods of making and using such antibodies, and recombinant DNA molecules that define the structural gene coding for the polypeptides are also contemplated as within the scope of the present invention.

.Beta.3 Integrin Subunit Specific Polypeptides, Cdnas Which Encode These Polypeptides And Methods Of Producing These Polypeptides

US Patent:

5661005, Aug 26, 1997

Filed:

Feb 2, 1996

Appl. No.:

8/597583

Inventors:

Sanford Shattil - Narberth PA
Timothy O'Toole - San Diego CA
Mark Ginsberg - San Diego CA

Assignee:

Trustees of the University of Pennsylvania - Philadelphia PA
Scripps Research Institute - La Jolla CA

International Classification:

C12N 1512

US Classification:

435 691

Abstract:

beta. sub. 3 integrin subunit specific polypeptides, cDNAs which encode these polypeptides and methods of producing these polypeptides are provided.

Platelet Gpiii P1.Sup.a1 And P1.Sup.a2 Epitopes, Their Preparation And Use

US Patent:

5939524, Aug 17, 1999

Filed:

Dec 9, 1991

Appl. No.:

7/808457

Inventors:

Ronald D. Bowditch - Encinitas CA
Robert McMillan - Del Mar CA
Mark H. Ginsberg - San Diego CA

Assignee:

The Scripps Research Institute - LaJolla CA

International Classification:

A61K 3800, A61K 3514, C07K 500, C07K 100

US Classification:

530324

Abstract:

Polypeptides and fusion polypeptides that immunologically mimic the native Pl. sup. A1 and Pl. sup. A2 determinants of platelet protein GPIIIa are disclosed. Also disclosed are DNA segments and recombinant DNA molecules that encode those polypeptides and fusion polypeptides and methods for expressing and using those determinants. Antibodies that immunoreact with one determinant or the other, but not both are also disclosed, as are methods of preparing and using those antibodies.